// App-Quantinova.ai

e15126 : Sorafenib (S) in HCC: Is there a role for starting at a total daily dose of 400mg?

Researchers

Presenter

  • Olugbenga Olanrele Olowokure

Principal Investigators

  • Brian Singeltary

  • Shimul Shah

  • Ross Ristagno

  • Alok kumar Dwivedi

  • Abhimanyu Ghose

  • Michelle Lynn Mierzwa

  • Tahir Latif

Medical Centers

  • University of Cincinnati Cancer Institute, Cincinnati, OH

  • Good Samaritan Hospital, Cincinnati, OHUniversity of Cincinnati, Cincinnati, OHTexas Tech University Health Sciences Center, Texas, TX

Locations

  • United States

Companies

  • N/A

Study Components

Therapeutic Area

  • N/A

Disease

  • N/A

Biomarkers

  • Alpha-fetoprotein

Drug/Treatment

  • Sorafenib

Outcome

  • Positive

Study Design

  • N/A

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • Final

Copyright © 2026. QuantiNova All rights reserved